SCHEMBL17115019

SCHEMBL17115019

Clc1ccc(Cc2noc(C(Cl)(Cl)Cl)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.52
NPC1 O15118 2/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
MAPK1 P28482 4/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
ERCC1 P07992 1/20 0.49
ERCC4 Q92889 1/20 0.49
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 3/20 0.45
TDP1 Q9NUW8 1/20 0.41
NOTUM Q6P988 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
GAA P10253 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100748 0.85 STAT3 (0.42) STAT3NPC1HTTRAB9AMAPK1
SCHEMBL432480 0.85 NPC1 (0.53) STAT3NPC1HTTRAB9AMAPK1
SCHEMBL18603150 0.81 STAT3 (0.51) STAT3NPC1HTTRAB9AMAPK1
SCHEMBL17115051 0.81 STAT3 (0.45) STAT3NPC1HTTRAB9AMAPK1
SCHEMBL9670480 0.75 MAPT (0.58) NPC1HTTRAB9AMAPK1L3MBTL1
SCHEMBL6980080 0.73 MAPT (0.57) NPC1HTTRAB9AMAPK1L3MBTL1
SCHEMBL21824541 0.73 CNR1 (0.46) STAT3RAB9AERCC1ERCC4MAPT
SCHEMBL17115046 0.73 STAT3 (0.43) STAT3NPC1RAB9AMAPK1L3MBTL1
SCHEMBL12128279 0.72 NPC1 (0.50) NPC1HTTRAB9AMAPK1L3MBTL1
SCHEMBL11840368 0.71 HDAC3 (0.45) STAT3NPC1HTTRAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT STAT3 4686/4885NPC1 1192/4885HTT 9/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT STAT3 4683/4885NPC1 1323/4885HTT 8/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT STAT3 4686/4885NPC1 1192/4885HTT 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.